California Agency Awards $9 Million to Enloe Health for Northern California Regenerative Medicine Access Center
The Chico site is expected to launch by January 2027 and will initially focus on approved CAR-T therapies and trials for blood cancers, autoimmune diseases, and rare genetic diseases.

Key Points
- The California Institute for Regenerative Medicine (CIRM) has awarded $9 million to Enloe Health in Chico to establish a Community Care Center of Excellence for regenerative medicine access.
- The Northern California center will connect patients with FDA-approved cell and gene therapies, clinical trials, support resources, and workforce training, with an expected launch by January 2027.
- CIRM’s board also approved more than $195 million at the same meeting for discovery research, clinical trials, and education programs.
The California Institute for Regenerative Medicine (CIRM), the state stem cell and gene therapy research funding agency, approved Enloe Health in Chico, California, to receive $9 million to establish a Community Care Center of Excellence (CCCE) aimed at helping people in Northern California access regenerative medicine therapies closer to home. The center will connect people in Chico and surrounding communities with FDA-approved cell and gene therapies, clinical trials studying new cell and gene therapies, patient support resources, and workforce training opportunities.
Stay updated on Cell & Gene news
Thanks! Your signup has been saved.
The center will first focus on delivering approved CAR-T therapies and on clinical trials for conditions such as blood cancers, autoimmune diseases, and rare genetic diseases.
“Every person in California should be able to access the most promising medical advances, including cell and gene therapies that are changing what is possible for serious and life-threatening diseases,” said Shyam Patel, Associate Vice President of Patient Access. “By expanding CIRM’s Clinical Network to include a site in Northern California, CIRM is helping bring clinical trial opportunities, approved therapies, trusted information, and patient support closer to the communities that need them.”
At the same meeting, board members approved more than $195 million to support discovery research, clinical trials, and education programs.
Growing Clinical Network
CIRM launched the CCCE program in 2025 as a first-of-its-kind effort to make regenerative medicine therapies and clinical trials more accessible for Californians who live far from major medical centers where most trials and FDA-approved therapies are administered. CIRM’s first CCCEs received $27 million to establish sites serving South L.A., the Inland Empire and Desert Region, and the Central Valley. CIRM’s four CCCEs and nine Alpha Clinics — world-class medical centers delivering cell and gene therapy clinical trials and approved therapies — together make up a Clinical Network that puts advanced therapies and clinical trials within less than an hour and a half drive for roughly 9 out of 10 Californians.
In addition to the Clinical Network, CIRM has a Patient Support Program that provides financial support for people in California to help overcome financial barriers to clinical trial participation. These include barriers such as transportation costs, food, and housing. The program only supports access for people in California participating in CIRM-funded clinical trials.
The Clinical Network site at Enloe Health is expected to launch by January 2027 and will work with community partners to address informational, economic, and social barriers that can prevent people from participating in research. People who are interested in learning about clinical trials being run in CIRM’s Clinical Network can browse clinical trials.
“This award is about meeting patients where they are and making it easier for families in Northern California to learn about and access regenerative medicine therapies and clinical trials,” said Maria Gonzalez Bonneville, CIRM Chair of the Access & Affordability Working Group and Board Vice Chair. “Through local partnerships and patient-centered support, the center will help reduce barriers that can keep people from benefiting from the next generation of therapies. This latest Clinical Network site is a core part of CIRM’s vision of ensuring that all Californians, regardless of location or background, have access to advanced cell and gene therapies and clinical trials.”
Created by California voters, CIRM funds stem cell and gene therapy research with the goal of accelerating treatments for patients with unmet medical needs. With $5.5 billion in funding allocated through Proposition 71 in 2004 and Proposition 14 in 2020, CIRM supports stem cell and gene therapy discoveries from inception through clinical trials, trains a workforce in California to fill jobs in the state’s biotech and biomedical research industry, and creates infrastructure to make clinical trials accessible throughout California.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
Similar stories
UConn Health Launches CAR-T Cell Therapy Program for Blood Cancers
Rznomics’ RNA-Editing Gene Therapy Receives EU Orphan Designation for Glioma
Zymeworks Licenses Trispecific T Cell Engager Targeting DLL3 to Roche
AbelZeta Receives FDA RMAT and Fast Track Designations for Anti-CD20/CD19 Bispecific CAR-T Therapy in Relapsed or Refractory Large B-Cell Lymphoma
Cabaletta Bio Reports One-Year Rese-cel Responses in Dermatomyositis and Safety Profile Across 71 Autoimmune Disease Patients
Kyverna Therapeutics Reports One-Year Phase 2 Results for CAR T-Cell Therapy in Stiff Person Syndrome
Fate Therapeutics Presents Updated Preliminary Data on iPSC-Derived CAR-T for Active Lupus Nephritis
Octane Biotech and Currus Biologics Automate CAR T-Cell Therapy Manufacturing







